Glucose News and Research

RSS

Phase 3 clinical study demonstrates efficacy of metformin therapy in type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from a randomized, double-blind Phase 3 clinical study in adults with type 2 diabetes inadequately controlled on metformin therapy alone.

24 Sep 2010

Takeda underscores commitment to ACTOS following FDA and EMA announcements for rosiglitazone

Following today’s announcements by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for rosiglitazone in the U.S. and Europe, Takeda Pharmaceuticals North America, Inc. and Takeda Pharmaceuticals Europe Limited underscore the company’s commitment to ACTOS® (pioglitazone HCl) and ACTOS-containing medications, and to the millions of people living with type 2 diabetes.

24 Sep 2010

Study reveals elevated risk of type 2 diabetes in South Asians than other Asian immigrants

South Asians living in the United States are at much higher risk for type 2 diabetes than are whites and immigrants from other Asian countries, a new small study reveals.

23 Sep 2010

Linagliptin clinical trial data shows positive result for type 2 diabetes treatment

New data from the linagliptin late stage clinical trial programme were presented this week at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD).

23 Sep 2010

Over one in three diabetics do not take insulin as prescribed

More than one in three diabetes patients skip doses or fail to take their insulin as prescribed, stating that they have done so on average three times in the last month, and 77 percent of physicians estimate that in reality this number could be as high as six doses, according to the Global Attitudes of Patients and Physicians in Insulin Therapy (GAPP™) survey, released today by Novo Nordisk.

23 Sep 2010

Generex presents study results of Oral-lyn insulin spray at EASD Annual Meeting

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it is presenting study results at the 46th Annual Meeting of the European Association for the Study of Diabetes being held in Stockholm, Sweden, 20 - 24 September, 2010.

23 Sep 2010

Intarcia Therapeutics presents ITCA 650 phase 2 study results for type 2 diabetes

Intarcia Therapeutics, Inc. presented today final results of a 24-week phase 2 clinical study of ITCA 650 (DUROS continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden.

23 Sep 2010

Boehringer Ingelheim to present linagliptin Phase III data at 46th EASD

New Phase III data found that investigational linagliptin therapy resulted in significant reductions in blood sugar as measured by hemoglobin A1c (HbA1c) when compared to placebo, both when added to sulfonylurea (SU) in inadequately controlled type 2 diabetes (T2D) patients, and when administered as monotherapy in T2D patients for whom metformin is inappropriate.

22 Sep 2010

Echo commences development of new transdermal biosensor for continuous lactate monitoring

Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that it is beginning a development program designed to create a new transdermal biosensor for continuous lactate monitoring to be used in critical care and sports medicine.

21 Sep 2010

ChemoCentryx presents CCX140 clinical data at EASD

ChemoCentryx, Inc., today announced that it reported positive preclinical and Phase I study results at the European Association for the Study of Diabetes (EASD). CCX140, a novel, orally bioavailable small molecule antagonist of the chemokine receptor CCR2, improved metabolic function while significantly reducing inflammatory macrophages found in adipose tissue in an animal model, and was well tolerated in Phase I clinical trials.

21 Sep 2010

Lixisenatide experimental diabetes drug shows potential in trial

Researchers at the R&D section of drug maker Sanofi Aventis have confirmed this Monday that a study of its experimental diabetes drug showed better blood sugar control than placebo.

21 Sep 2010

Biomarkers may help predict children at high risk of developing type 2 diabetes

Children who have a high risk of developing type 2 diabetes might be identified earlier by way of tell-tale genetic indicators known as biomarkers. Some of those new biomarkers might be pinpointed in research led by Nancy F. Butte and funded by the U.S. Department of Agriculture (USDA) and the U.S. Department of Health and Human Service's National Institutes of Health.

20 Sep 2010

Elias Shaker to sell Generex's novel consumer products

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has entered into a sales agreement with Elias Shaker & Company, a leading national full-service consumer product brokerage firm, to represent Generex's novel consumer products to national and regional retail and wholesale accounts in the USA.

20 Sep 2010

Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients

Bristol-Myers Squibb Company and AstraZeneca today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride (sulphonylurea) therapy produced significant reductions in glycosylated hemoglobin levels (HbA1c) in adult patients with type 2 diabetes compared to glimepiride alone.

20 Sep 2010

Sanofi-aventis releases Lantus(R) study results for type 2 diabetes

Sanofi-aventis announced today results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.

20 Sep 2010

Phase III trial results of lixisenatide for type 2 diabetes presented at 46th EASD

Sanofi-aventis announced today the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.

20 Sep 2010

Lisofylline drug effective for Type 2 diabetes

Australian scientists, in association with US pharmaceutical company DiaKine Therapeutics, have shown that a drug candidate, Lisofylline, could be useful in treating Type 2 diabetes.

20 Sep 2010

Improper biological clocks tend to develop diabetes, obesity: Research

Biologists have found that a key protein that regulates the biological clocks of mammals also regulates glucose production in the liver and that altering the levels of this protein can improve the health of diabetic mice.

20 Sep 2010

Anthem Blue Cross hosts Hmong Health Awareness Fair with local health and community agencies

Tomorrow, Anthem Blue Cross State Sponsored Business will team with local health and community agencies to host the Hmong Health Awareness Fair. Local health and community organizations will be on hand to provide local families free health screenings, vaccines and health information. The health fair will take place from 9:00 a.m. to 3: p.m. at the Asian Village Shopping Center located at 4903 E. Kings Canyon Road.

18 Sep 2010

POWER study: Women with diabetes have C-section, complications during pregnancy

Nearly half of women with diabetes prior to pregnancy have a potentially-avoidable C-section and their babies are twice as likely to die as those born to women without diabetes, according to the POWER study.

18 Sep 2010

Glucose News and Research

Phase 3 clinical study demonstrates efficacy of metformin therapy in type 2 diabetes

Takeda underscores commitment to ACTOS following FDA and EMA announcements for rosiglitazone

Study reveals elevated risk of type 2 diabetes in South Asians than other Asian immigrants

Linagliptin clinical trial data shows positive result for type 2 diabetes treatment

Over one in three diabetics do not take insulin as prescribed

Generex presents study results of Oral-lyn insulin spray at EASD Annual Meeting

Intarcia Therapeutics presents ITCA 650 phase 2 study results for type 2 diabetes

Boehringer Ingelheim to present linagliptin Phase III data at 46th EASD

Echo commences development of new transdermal biosensor for continuous lactate monitoring

ChemoCentryx presents CCX140 clinical data at EASD

Lixisenatide experimental diabetes drug shows potential in trial

Biomarkers may help predict children at high risk of developing type 2 diabetes

Elias Shaker to sell Generex's novel consumer products

Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients

Sanofi-aventis releases Lantus(R) study results for type 2 diabetes

Phase III trial results of lixisenatide for type 2 diabetes presented at 46th EASD

Lisofylline drug effective for Type 2 diabetes

Improper biological clocks tend to develop diabetes, obesity: Research

Anthem Blue Cross hosts Hmong Health Awareness Fair with local health and community agencies

POWER study: Women with diabetes have C-section, complications during pregnancy

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News